ICER to Investigate Treatments for Autoimmune Disease Myasthenia Gravis

ICER will determine the efficacy and economic outcomes of two treatments for autoimmune disease Myasthenia Gravis where neuromuscular junctions are weakened. It affects between 14 and 20 people per 100,000 in the US with a typical yearly cost of $15,675 for payers. Antibody fragment efgartigimod and monoclonal antibody eculizumab will be assessed, with a public meeting to be held in September of this year. The FDA is expected to rule on efgartigimod in mid-December while eculizumab received approval in late 2017.

“This project will evaluate the health and economic outcomes of both eculizumab and efgartigimod for myasthenia gravis. The ICER value framework includes both quantitative and qualitative comparisons across treatments to ensure that the full range of benefits and harms – including those not typically captured in the clinical evidence such as innovation, public health effects, reduction in disparities, and unmet medical needs – are considered in the judgments about the clinical and economic value of the interventions.” Read more here.

(Source: ICER, 3/15/2021)